Recent Updates — BLSM
BlossomHill Therapeutics reported second quarter 2026 financial results on September 18, 2026. The company posted a net loss of $23.8 million, or $(8.75) per share, compared to a $13.2 million loss in the prior year period. Research and development expenses increased to $21.4 million from $12.5 million, driven by clinical trial costs for BH-30643 and IND-enabling studies for BH-501284. General and administrative expenses rose to $3.3 million from $1.6 million. Cash and cash equivalents totaled $95.4 million as of June 30, 2026. The company also announced the completion of an upsized initial public offering in August 2026, generating approximately $168.3 million in gross proceeds from the sale of 10,516,240 shares. Additionally, BlossomHill received FDA Fast Track designation for BH-30643 to treat advanced EGFR C797S-positive non-small cell lung cancer and expanded its board with two new appointments. BlossomHill Therapeutics is a clinical-stage biopharmaceutical company developing small molecule medicines for cancer treatment.
BlossomHill Therapeutics released updated data from its Phase 1/2 SOLARA trial for BH-30643 in NSCLC patients with EGFR C797S resistance. The drug demonstrated a 45% objective response rate and 88% disease control rate in 40 evaluable patients, with a favorable safety profile showing only 9% dose reduction rates. The company plans to initiate a global Phase 2 study for this indication in Q1 2027. BlossomHill Therapeutics is a clinical-stage biopharmaceutical company developing innovative small molecule medicines for cancer treatment.
BlossomHill Therapeutics, Inc. completed its initial public offering on August 10, 2026, selling 9,375,000 shares of common stock at $16.00 per share. The transaction generated approximately $150.0 million in aggregate gross proceeds before deducting underwriting discounts and offering expenses. Concurrently, the company filed an amended and restated certificate of incorporation and adopted new bylaws effective immediately prior to the IPO closing. BlossomHill Therapeutics operates in the biotechnology industry, focusing on the discovery and development of therapeutic treatments.